A5013718591- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Acute Ischemic Stroke Management
- Lung Cancer Treatments and Mutations
- Antiplatelet Therapy and Cardiovascular Diseases
- Cerebrovascular and Carotid Artery Diseases
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Diabetes Treatment and Management
- Analytical Methods in Pharmaceuticals
- Stroke Rehabilitation and Recovery
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Intracranial Aneurysms: Treatment and Complications
- Esophageal Cancer Research and Treatment
- Traumatic Brain Injury and Neurovascular Disturbances
- Cardiac, Anesthesia and Surgical Outcomes
- Antibiotics Pharmacokinetics and Efficacy
- Geology and Paleoclimatology Research
- Intracerebral and Subarachnoid Hemorrhage Research
- Methane Hydrates and Related Phenomena
- Inflammatory mediators and NSAID effects
- Venous Thromboembolism Diagnosis and Management
- Lung Cancer Research Studies
Qingdao National Laboratory for Marine Science and Technology
2017-2025
Nanjing Medical University
2013-2025
China Pharmaceutical University
2009-2025
Sichuan Provincial Hospital of Traditional Chinese Medicine
2024
Jiangsu Hengrui Medicine (China)
2017-2023
Guangzhou Chest Hospital
2015-2023
Guangdong Polytechnic of Industry and Commerce
2019-2023
China Medical University
2018-2022
Capital Normal University
2022
Chinese Academy of Surveying and Mapping
2022
<h3>Importance</h3> Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated squamous cell carcinoma. <h3>Objective</h3> To evaluate efficacy and adverse events of camrelizumab plus chemotherapy vs placebo as a treatment <h3>Design, Setting, Participants</h3> This randomized, double-blind, placebo-controlled,...
Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy of pyrotinib versus lapatinib, both combination with capecitabine, women human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer open-label, multicenter, randomized II study.Chinese patients HER2-positive relapsed or previously treated taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400...
Abstract Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision targeted therapies. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we conducted the FUTURE trial (ClinicalTrials.gov identifier: NCT03805399), phase Ib/II subtyping-based genomic biomarker-guided umbrella trial, to evaluate efficacy of these Patients refractory metastatic TNBC were enrolled...
Targeted therapies against non-small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of pyrotinib in patients with HER2-mutant advanced NSCLC a prospective, multicenter, open-label, single-arm, phase II study.Patients stage IIIB or IV adenocarcinoma who were previously treated platinum-based chemotherapy enrolled to receive at dose 400 mg/d for 21-day cycles. The primary end point was objective response rate per...
This study retrospectively collected clinical data from 480 patients with connective tissue diseases (CTDs) at Nanjing First Hospital between August 2019 and December 2023 to develop validate a multi-classification machine learning (ML) model for assessing depression risk. Addressing the limitations of traditional assessment tools, six ML models were constructed using univariate analysis LASSO algorithm, categorical boosting (Catboost) emerging as best performer, demonstrating strong...
Abstract Background Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common event related to camrelizumab, an immune checkpoint inhibitor, but lack comprehensive analyses. In this study, we conducted analyses on RCCEP in advanced hepatocellular carcinoma (HCC) patients treated camrelizumab monotherapy. Methods Data were derived from a Chinese nationwide, multicenter phase 2 trial...
Background: Pyrotinib is an irreversible pan-ErbB inhibitor targeting epidermal growth factor receptor, human receptor 2 (HER2), and HER4. This randomized, double-blinded phase 3 study evaluated the efficacy safety of pyrotinib plus capecitabine for HER2-positive local relapsed or metastatic breast cancer. Methods: Patients who had been treated with trastuzumab taxanes were randomized (2:1) to receive either oral placebo (400 mg, qd) (1,000 mg/m2, bid on days 1–14) 21-day cycles, using...
Background This study aimed to evaluate the antitumor activity of camrelizumab, an antiprogrammed cell death-1 antibody, in pretreated recurrent or metastatic nasopharyngeal carcinoma (NPC) and explore predictive biomarkers. Methods Patients with (not amenable locally curative treatment) NPC who had failed at least two lines chemotherapy were eligible receive camrelizumab (200 mg intravenously every 2 weeks) for years until disease progression, intolerable adverse events, withdrawal...
Background Emerging clinical data suggest that an immune checkpoint inhibitor in combination with antiangiogenic agent is a reasonable strategy for multiple malignancies. We assessed the of camrelizumab apatinib pretreated advanced primary liver cancer (PLC, cohort A) from multicohort phase Ib/II trial. Methods Patients PLC after prior systemic treatment(s) were administered (3 mg/kg, once every 2 weeks) plus (125, 250, 375, or 500 mg; per day) 3+3 dose-escalation stage and subsequent...
Abstract Background Immune checkpoint inhibitors had a great effect in triple-negative breast cancer (TNBC); however, they benefited only subset of patients, underscoring the need to co-target alternative pathways and select optimal patients. Herein, we investigated patient subpopulations more likely benefit from immunotherapy inform effective combination regimens for TNBC Methods We conducted exploratory analyses FUSCC cohort characterize novel selection method actionable targets...
Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. We aimed to assess the efficacy safety of novel combination famitinib, camrelizumab, advanced TNBC.This open-label, single-arm, phase II study enrolled patients with previously untreated, advanced, TNBC (CD8 IHC...
Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We further assessed addition of pyrotinib to trastuzumab docetaxel the neoadjuvant setting. In this multicenter, double-blind, phase 3 study (PHEDRA), treatment-naive women early or locally advanced cancer were randomly assigned (1:1) receive four cycles oral placebo (400 mg) once daily, intravenous (8 mg/kg loading dose,...